Literature DB >> 16476846

The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling.

Wen Zhao1, Qunying Yuan, Jiang Qian, Jason R Waggoner, Anand Pathak, Guoxiang Chu, Bryan Mitton, Xiaoyin Sun, Jay Jin, Julian C Braz, Harvey S Hahn, Yehia Marreez, Faisal Syed, Piero Pollesello, Arto Annila, Hong-Sheng Wang, Jo El J Schultz, Jeffery D Molkentin, Stephen B Liggett, Gerald W Dorn, Evangelia G Kranias.   

Abstract

BACKGROUND: Phospholamban (PLN) is an inhibitor of the Ca2+ affinity of sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2). The amino acid sequence of PLN is highly conserved, and although all species contain asparagine (Asn), human PLN is unique in containing lysine (Lys) at amino acid 27. METHODS AND
RESULTS: Human PLN was introduced in the null background. Expression of human PLN, at similar levels to mouse wild-type PLN, resulted in significant decreases in the affinity of SERCA2 for Ca2+, attributed to unique spatial conformation of this PLN form and increases in its monomeric active unit compared with mouse PLN. The increased inhibition by human PLN was associated with attenuated cardiac contractility in the intact-animal, organ, and cardiomyocyte levels and with depressed calcium kinetics. These inhibitory effects could not be fully reversed even on maximal isoproterenol stimulation. There were no alterations in the expression levels of SERCA2, calsequestrin, ryanodine receptor, and FKBP12, although the sodium/calcium exchanger and the L-type Ca2+ channel expression levels were upregulated. The depressed function resulted in increased heart/body weight ratios and phosphorylation levels of Akt, p38, and Erk1/2.
CONCLUSIONS: Human PLN may play a more inhibitory role than that of other species in Ca2+ cycling. Expression of human PLN in the mouse is compensated by alterations in Ca2+-handling proteins and cardiac remodeling in an effort to normalize cardiac contractility. Thus, the unique amino acid sequence of human PLN may be critical in maintaining a high cardiac reserve, which is of paramount importance in the regulation of human cardiac function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476846     DOI: 10.1161/CIRCULATIONAHA.105.583351

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Characterizing phospholamban to sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) protein binding interactions in human cardiac sarcoplasmic reticulum vesicles using chemical cross-linking.

Authors:  Brandy L Akin; Larry R Jones
Journal:  J Biol Chem       Date:  2012-01-14       Impact factor: 5.157

2.  Solid-state (2)H and (15)N NMR studies of side-chain and backbone dynamics of phospholamban in lipid bilayers: investigation of the N27A mutation.

Authors:  Shidong Chu; Aaron T Coey; Gary A Lorigan
Journal:  Biochim Biophys Acta       Date:  2009-10-17

3.  PLN Foundation.

Authors:  Evangelia G Kranias; Pieter A Doevendans; Pieter C Glijnis; Roger J Hajjar
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

4.  Silencing calcineurin A subunit reduces SERCA2 expression in cardiac myocytes.

Authors:  Anand Mohan Prasad; Giuseppe Inesi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

Review 5.  The Ca2+ pumps of the endoplasmic reticulum and Golgi apparatus.

Authors:  Ilse Vandecaetsbeek; Peter Vangheluwe; Luc Raeymaekers; Frank Wuytack; Jo Vanoevelen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

6.  SERCA2a superinhibition by human phospholamban triggers electrical and structural remodeling in mouse hearts.

Authors:  Hong-Sheng Wang; Demetrios A Arvanitis; Min Dong; Paul J Niklewski; Wen Zhao; Chi Keung Lam; Evangelia G Kranias; Despina Sanoudou
Journal:  Physiol Genomics       Date:  2011-01-25       Impact factor: 3.107

7.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 8.  Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Authors:  Wolfgang Poller; Roger Hajjar; Heinz-Peter Schultheiss; Henry Fechner
Journal:  Cardiovasc Res       Date:  2010-02-22       Impact factor: 10.787

9.  Partial downregulation of junctin enhances cardiac calcium cycling without eliciting ventricular arrhythmias in mice.

Authors:  Qunying Yuan; Peidong Han; Min Dong; Xiaoping Ren; Xiaoyang Zhou; Shan Chen; W Keith Jones; Guoxiang Chu; Hong-Sheng Wang; Evangelia G Kranias
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

10.  The anti-apoptotic protein HAX-1 is a regulator of cardiac function.

Authors:  Wen Zhao; Jason R Waggoner; Zhi-Guo Zhang; Chi Keung Lam; Peidong Han; Jiang Qian; Paul M Schroder; Bryan Mitton; Aikaterini Kontrogianni-Konstantopoulos; Seth L Robia; Evangelia G Kranias
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.